RxDoctor Payments DataLook up a doctor →

Nadim Nasir, MD

Clinical Cardiac Electrophysiology · Houston, TXNPI 1952364788

Payments from drug & device makers

$162,100in general payments, 2019–2025

Across 913 payments — averaging $177.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$107K
  • Johnson & Johnson$33K
  • Pfizer$6K
  • E.r. Squibb & Sons, L.L.C.$4K
  • Abbott$3K
  • Medtronic$1K
  • plus $7K from 38 others

What the payments were for

  • Consulting fees$45,00028%
  • Speaking & faculty fees$99,92062%
  • Travel & lodging$1,0251%
  • Food & beverage$16,01710%
  • Education$1390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$162,100 in reported general payments places this provider in the 75th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$871,309
Medicare patients
937
Services billed
8,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban539$656,383
XareltoRivaroxaban248$292,375
EntrestoSacubitril/Valsartan135$180,185
FarxigaDapagliflozin Propanediol79$75,501
Repatha SureclickEvolocumab83$62,548
MultaqDronedarone Hcl28$50,941
Dabigatran EtexilateDabigatran Etexilate Mesylate44$13,717
Flecainide Acetate206$11,924
Metoprolol Succinate606$10,153
Repatha SyringeEvolocumab11$8,771
Propafenone Hcl ErPropafenone Hcl18$8,632
Dofetilide38$8,318
Praluent PenAlirocumab12$6,487
Rosuvastatin Calcium243$4,010
Atorvastatin Calcium295$3,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$6,071$656,383539 claims
Johnson & JohnsonXarelto$32,622$292,375248 claims
NovartisEntresto$696$180,185135 claims
AstraZenecaFarxiga$257$75,50179 claims
Sanofi-aventis U.S. LLCMultaq$792$50,94128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →